Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 6	FEB 10	COMPENDEX reloaded and enhanced
NEWS 7	FEB 11	WTEXTILES reloaded and enhanced
NEWS 8	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 19	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 22	APR 07	STN is raising the limits on saved answers
NEWS 23	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 25	APR 28	CAS patent authority coverage expanded
NEWS 26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 27	APR 28	Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:33:38 ON 06 MAY 2009

=> file retg
'RETG' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 20:33:51 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7
DICTIONARY FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10575790dd.str





chain nodes :
21 22 23 24 25 27 29 43 44
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 26 28 30 31 32 33
34 35 36 37 38 39 40 41 42
ring/chain nodes :
18 20
chain bonds :
10-12 15-18 18-20 20-21 22-23 23-24 25-26 27-28 29-30 36-43 40-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17 26-31 26-34 28-35 28-38 30-39 30-42 31-32 32-33 33-34
35-36 36-37 37-38 39-40 40-41 41-42
exact/norm bonds :
7-11 9-10 10-11 20-21 26-31 26-34 28-35 28-38 30-39 30-42 31-32 32-33
33-34 35-36 36-37 36-43 37-38 39-40 40-41 40-44 41-42
exact bonds :
7-8 8-9 10-12 15-18 18-20 25-26 27-28 29-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 22-23
23-24
isolated ring systems :
containing 1 : 7 : 12 :

G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:Atom 27:CLASS 28:Atom
29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:CLASS 44:CLASS 50:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 20:34:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.01

L2 37 SEA SSS FUL L1

=>
Uploading C:\Program Files\STNEXP\Queries\10575790cc.str





chain nodes :
21 22 23 24 25 27 29 43 44
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 26 28 30 31 32 33
34 35 36 37 38 39 40 41 42
ring/chain nodes :
18 20
chain bonds :
5-7 10-12 15-18 18-20 20-21 22-23 23-24 25-26 27-28 29-30 36-43 40-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17 26-31 26-34 28-35 28-38 30-39 30-42 31-32 32-33 33-34
35-36 36-37 37-38 39-40 40-41 41-42

exact/norm bonds :
7-11 9-10 10-11 20-21 26-31 26-34 28-35 28-38 30-39 30-42 31-32 32-33
33-34 35-36 36-37 36-43 37-38 39-40 40-41 40-44 41-42
exact bonds :
5-7 7-8 8-9 10-12 15-18 18-20 25-26 27-28 29-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 22-23
23-24
isolated ring systems :
containing 1 : 7 : 12 :

G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:Atom 27:CLASS 28:Atom
29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:CLASS 44:CLASS

L3   STRUCTURE UPLOADED

=> s l3 sss full
FULL SEARCH INITIATED 20:34:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   224 TO ITERATE

100.0% PROCESSED   224 ITERATIONS   38 ANSWERS
SEARCH TIME: 00.00.01

L4   38 SEA SSS FUL L3

=> file capl
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   371.76   371.98

FILE 'CAPLUS' ENTERED AT 20:34:51 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 5 May 2009 (20090505/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2
L5            6 L2

=> s l4
L6            5 L4

=> s l5 or l6
L7            8 L5 OR L6

=> d l7 1-8 ibib hitstr

L7   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:1158632  CAPLUS
DOCUMENT NUMBER:          149:402366
TITLE:                    Preparation of aminopyridine derivatives, particularly
                          3-(aminopyridinyl)-5-(alkoxyphenyl)-1,2,4-oxadiazoles,
                          as immunomodulating S1P1/EDG1 receptor agonists
INVENTOR(S):              Bolli, Martin; Mathys, Boris; Mueller, Claus; Nayler,
                          Oliver; Steiner, Beat; Velker, Joerg
PATENT ASSIGNEE(S):       Actelion Pharmaceuticals Ltd, Switz.
SOURCE:                   PCT Int. Appl., 121pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 2008114157         A1    20080925    WO 2008-IB50742        20080229
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       WO 2007-IB50921     A  20070316
OTHER SOURCE(S):          MARPAT 149:402366
IT   1062670-28-3P, 3-[2-Ethyl-4-[5-[2-[(isopropyl)(methyl)amino]-6-
     methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionic acid
     1062670-96-5P, 3-[4-[5-(2-Diethylamino-6-methylpyridin-4-
     yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenyl]propionic acid
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (drug candidate; preparation of aminopyridine derivs. as immunomodulating
        S1P1/EDG1 receptor agonists)
```

RN 1062670-28-3 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-[methyl(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1062670-96-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[2-(diethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methyl- (CA INDEX NAME)



IT 1062673-09-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)
RN 1062673-09-9 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-[(1-methylethyl)amino]-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



IT 1062669-77-5P, 3-[2-Ethyl-4-[5-[2-[(ethyl)(methyl)amino]-6-methylpyridin-4-yl][1,2,4]oxadiazol-3-yl]-6-methylphenyl]propionic acid
RL: SPN (Synthetic preparation); PREP (Preparation)
(drug candidate; preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)
RN 1062669-77-5 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[5-[2-(ethylmethylamino)-6-methyl-4-pyridinyl]-1,2,4-oxadiazol-3-yl]-6-methyl- (CA INDEX NAME)



IT 1062673-25-9P, 3-[2-Ethyl-6-methyl-4-[5-[2-methyl-6-(morpholin-4-yl)pyridin-4-yl][1,2,4]oxadiazol-3-yl]phenyl]propionic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminopyridine derivs. as immunomodulating S1P1/EDG1 receptor agonists)
RN 1062673-25-9 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-(4-morpholinyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:411236 CAPLUS
DOCUMENT NUMBER: 148:403230
TITLE: Preparation of diaryloxadiazole derivatives for use as antiinflammatory and immunosuppressive agents
INVENTOR(S): Albert, Rainer; Cooke, Nigel Graham; Lewis, Ian; Weiler, Sven; Zecri, Frederic
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008037476	A1	20080403	WO 2007-EP8431	20070927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2007302262 A1 20080403 AU 2007-302262 20070927
PRIORITY APPLN. INFO.: EP 2006-121495 A 20060929
WO 2007-EP8431 W 20070927

OTHER SOURCE(S): MARPAT 148:403230

IT 1016261-25-8P 1016261-26-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryloxadiazole derivs. for use as antiinflammatory and immunosuppressive agents)

RN 1016261-25-8 CAPLUS
CN L-Phenylalanine, 4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-26-9 CAPLUS
CN D-Phenylalanine, 4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:322210 CAPLUS
DOCUMENT NUMBER: 148:355634
TITLE: Pyridin-3-yl derivatives as immunomodulating agents and their preparation, pharmaceutical compositions and use in the treatment of immune system disorders
INVENTOR(S): Bolli, Martin; Lehmann, David; Mathys, Boris; Mueller, Claus; Nayler, Oliver; Steiner, Beat; Velker, Joerg
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 82pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008029370	A1	20080313	WO 2007-IB53593	20070906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2006-IB53187 A 20060908
OTHER SOURCE(S): MARPAT 148:355634
IT 1011476-25-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of pyridinyl derivs. as immunomodulating agents useful in the treatment of immune system disorders)
RN 1011476-25-7 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[5-methyl-6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:322202 CAPLUS
DOCUMENT NUMBER: 148:331565
TITLE: Pyridin-4-yl derivatives as immunomodulating agents and their preparation, pharmaceutical compositions and use in the treatment of immune system disorders
INVENTOR(S): Bolli, Martin; Lehmann, David; Mathys, Boris; Mueller, Claus; Nayler, Oliver; Steiner, Beat; Velker, Joerg
PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd., Switz.
SOURCE: PCT Int. Appl., 132pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2008029371 A1 20080313 WO 2007-IB53594 20070906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: WO 2006-IB53147 A 20060907
OTHER SOURCE(S): MARPAT 148:331565
IT 1011264-28-0P 1011264-30-4P 1011264-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridinyl derivs. as immunomodulating agents useful in the treatment of immune system disorders)
RN 1011264-28-0 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-4-[5-(2-ethyl-6-methyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-6-methyl- (CA INDEX NAME)



RN 1011264-30-4 CAPLUS
CN Benzenepropanoic acid, 2-ethyl-6-methyl-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 1011264-32-6 CAPLUS
CN Benzenepropanoic acid, 2,6-dimethyl-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:81270 CAPLUS
DOCUMENT NUMBER: 146:337810
TITLE: SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties
AUTHOR(S): Yan, Lin; Huo, Pei; Hale, Jeffrey J.; Mills, Sander G.; Hajdu, Richard; Keohane, Carol A.; Rosenbach, Mark J.; Milligan, James A.; Shei, Gan-Ju; Chrebet, Gary; Bergstrom, James; Card, Deborah; Mandala, Suzanne M.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 828-831
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:337810
IT 856166-23-9P 856166-26-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, sphingosinephosphate receptor agonistic activity, pharmacokinetics, and structure-activity relationship of (oxadiazolylaryl)propionic acids using Heck coupling reaction)
RN 856166-23-9 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-26-2 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:548763 CAPLUS
DOCUMENT NUMBER: 145:180190
TITLE: Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor
AUTHOR(S): Vachal, Petr; Toth, Leslie M.; Hale, Jeffrey J.; Yan, Lin; Mills, Sander G.; Chrebet, Gary L.; Koehane, Carol A.; Hajdu, Richard; Milligan, James A.; Rosenbach, Mark J.; Mandala, Suzanne
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3684-3687
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 856166-11-5P 856166-29-5P 856167-04-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonists of sphingosine-1-phosphate 1 receptor)
RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-29-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856167-04-9 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:548762 CAPLUS
DOCUMENT NUMBER: 145:210970
TITLE: Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes
AUTHOR(S): Yan, Lin; Huo, Pei; Doherty, George; Toth, Lesile; Hale, Jeffrey J.; Mills, Sander G.; Hajdu, Richard; Keohane, Carol A.; Rosenbach, Mark J.; Milligan, James A.; Shei, Gan-Ju; Chrebet, Gary; Bergstrom, James; Card, Deborah; Quackenbush, Elizabeth; Wickham, Alexandra; Mandala, Suzanne M.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3679-3683
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:210970
IT 856166-09-1P 856166-11-5P 856166-12-6P
856166-13-7P 856166-14-8P 856166-15-9P
856166-16-0P 856166-29-5P 856166-34-2P
856166-74-0P 856166-82-0P 856166-88-6P
856166-89-7P 856166-90-0P 856167-04-9P
905308-11-4P 905308-18-1P 905308-20-5P
905308-32-9P 905308-36-3P 905308-38-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes)

RN 856166-09-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-12-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-bromo-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-13-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-methoxy-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-14-8 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-15-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-fluoro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-16-0 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[5-(2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-29-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-34-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-74-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-(1,1-difluoro-2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-82-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-88-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-89-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-90-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856167-04-9 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 905308-11-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-18-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-ethoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-20-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-methoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-32-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-(5-butyl-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-36-3 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[6-(2-methylpropyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 905308-38-5 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:564648 CAPLUS
DOCUMENT NUMBER: 143:97368
TITLE: Preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists
INVENTOR(S): Colandrea, Vincent J.; Doherty, George A.; Hale, Jeffrey J.; Huo, Pei; Legiec, Irene E.; Toth, Leslie; Vachal, Petr; Yan, Lin
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058848	A1	20050630	WO 2004-US41887	20041213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004299456	A1	20050630	AU 2004-299456	20041213
CA 2547198	A1	20050630	CA 2004-2547198	20041213
EP 1697333	A1	20060906	EP 2004-814111	20041213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1894225	A	20070110	CN 2004-80037208	20041213
JP 2007515432	T	20070614	JP 2006-545810	20041213
US 20080249093	A1	20081009	US 2006-575790	20060412
IN 2006DN02136	A	20070629	IN 2006-DN2136	20060419
PRIORITY APPLN. INFO.:			US 2003-530186P P	20031217
			WO 2004-US41887 W	20041213

OTHER SOURCE(S): CASREACT 143:97368; MARPAT 143:97368
IT 856166-09-1P, 3-[4-[5-(3-Cyano-4-isopropyloxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-11-5P, 3-[4-[5-(4-Isopropoxy-3-chlorophenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-12-6P, 3-[4-[5-(4-Isopropoxy-3-bromophenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-13-7P, 3-[4-[5-(4-Isopropoxy-3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-

methylphenyl]propanoic acid 856166-14-8P,
3-[4-[5-(4-Isopropoxy-3-methylphenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-15-9P,
3-[4-[5-(4-Isopropoxy-3-fluorophenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-16-0P,
3-[4-[5-[5-(2-Methylpropyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-23-9P,
2-Methyl-3-[4-[5-[3-(trifluoromethyl)-4-isopropoxyphenyl]-1,2,4-oxadiazol-
3-yl]-3-methylphenyl]propanoic acid 856166-24-0P,
2-Methyl-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-25-1P,
2-Methyl-3-[4-[5-(3-methyl-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-26-2P,
3-[4-[5-[3-(Trifluoromethyl)-4-isopropoxyphenyl]-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]butanoic acid 856166-27-3P,
3-[4-[5-(3-Cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]butanoic acid 856166-28-4P,
3-[4-[5-(3-Methyl-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]butanoic acid 856166-29-5P,
3-[4-[5-(5-Chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-32-0P,
3-[4-[5-(5-Chloro-6-isopropylaminopyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-34-2P,
3-[4-[5-[5-Chloro-6-[1-(trifluoromethyl)ethoxy]pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-35-3P,
3-[4-[5-[5-Chloro-6-(pyrrolidin-1-yl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-36-4P,
3-[4-[5-[5-Chloro-6-(morpholin-4-yl)pyridin-3-yl]-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-37-5P,
3-[4-[5-[5-Chloro-6-[(isopropyl)(methyl)amino]pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-38-6P,
3-[4-[5-[5-Chloro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-1,2,4-oxadiazol-3-
yl]-3-methylphenyl]butanoic acid 856166-39-7P,
3-[4-[5-[5-Chloro-6-[1-(trifluoromethyl)ethoxy]pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-40-0P,
3-[4-[5-[5-Chloro-6-(3,3-difluoropiperidin-1-yl)pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-41-1P,
3-[4-[5-[5-Chloro-6-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-42-2P,
3-[4-[5-[5-Trifluoromethyl-6-(morpholin-4-yl)pyridin-3-yl]-1,2,4-oxadiazol-
3-yl]-3-methylphenyl]butanoic acid 856166-48-8P,
3-[4-[5-(5-Chloro-6-isobutylpyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-50-2P,
3-[4-[5-[5-Iodo-6-(N-isopropyl-N-methylamino)pyridin-3-yl]-1,2,4-oxadiazol-
3-yl]-3-methylphenyl]propanoic acid 856166-51-3P,
3-[4-[5-[5-Cyano-6-(N-isopropyl-N-methylamino)pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-54-6P,
3-[4-[5-[6-(3,3-Difluoropyrrolidin-1-yl)-5-iodopyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-55-7P,
3-[4-[5-[6-(3,3-Difluoropyrrolidin-1-yl)-5-ethynylpyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-74-0P,
3-[4-[5-[5-(1,1-Difluoro-2-methylpropyl)pyridin-2-yl]-1,2,4-oxadiazol-3-
yl]-3-methylphenyl]propanoic acid 856166-75-1P,
3-[4-[5-(5-Cyano-6-ethoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-76-2P,
3-[4-[5-[5-Cyano-6-[1-(trifluoromethyl)ethoxy]pyridin-3-yl]-1,2,4-
oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-77-3P,
3-[4-[5-(5-Cyano-6-isobutylpyridin-3-yl)-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-78-4P,
3-[4-[5-[4-(1,1-Difluoro-2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-
methylphenyl]propanoic acid 856166-79-5P,
3-[4-[5-[5-Iodo-6-[1-(trifluoromethyl)ethoxy]pyridin-3-yl]-1,2,4-oxadiazol-

3-yl]-3-methylphenyl]propanoic acid 856166-80-8P,
3-[4-[5-[3-Chloro-4-(cyclopentyloxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-81-9P,
3-[4-[5-[3-Chloro-4-(2-methylpropoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-82-0P,
3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-83-1P,
3-[4-[5-[3-Chloro-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-84-2P,
3-[4-[5-(3,5-Dichloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-85-3P,
3-[4-[5-[3-Chloro-4-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-86-4P 856166-87-5P,
3-[4-[5-[3-Nitro-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-88-6P,
3-[4-[5-[3-Cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-89-7P,
3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)-2,2,2-trifluoroethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-90-0P
, 3-[4-[5-[3-Cyano-4-[((S)-1-methylpropyl)oxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-91-1P,
3-[4-[5-[4-(Trifluoromethyl)-6-[1-(trifluoromethyl)ethoxy]pyridin-3-yl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-92-2P
, 3-[4-[5-[4-Amino-6-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-94-4P,
3-[4-[5-[3-Cyano-4-[((S)-1-methylpropyl)oxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-95-5P,
3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)-2,2,2-trifluoroethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-96-6P,
3-[4-[5-[3-Cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856167-09-4P 856167-14-1P
856167-19-6P, erythro-(±)-2,3-Dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856167-21-0P, threo-(±)-2,3-Dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856167-30-1P, 3-[4-[5-[3-Chloro-4-(isopropylthio)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists)

RN 856166-09-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-12-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-bromo-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-13-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-methoxy-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-14-8 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-15-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-fluoro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-16-0 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[5-(2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-23-9 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-24-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,3-dimethyl- (CA INDEX NAME)



RN 856166-25-1 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-26-2 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-27-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-28-4 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-29-5 CAPLUS

CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-32-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-[(1-methylethyl)amino]-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-34-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-35-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(1-pyrrolidinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-36-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(4-morpholinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-37-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-[methyl(1-methylethyl)amino]-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-38-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-39-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-40-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(3,3-difluoro-1-piperidinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-41-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(3,3-difluoro-1-pyrrolidinyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-42-2 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[6-(4-morpholinyl)-5-(trifluoromethyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-48-8 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-chloro-6-(2-methylpropyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-50-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-iodo-6-[methyl(1-methylethyl)amino]-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-51-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-cyano-6-[methyl(1-methylethyl)amino]-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-54-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[6-(3,3-difluoro-1-pyrrolidinyl)-5-iodo-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-55-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[6-(3,3-difluoro-1-pyrrolidinyl)-5-ethynyl-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-74-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-(1,1-difluoro-2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-75-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-(5-cyano-6-ethoxy-3-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-76-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-cyano-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-77-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-cyano-6-(2-methylpropyl)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-78-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-(1,1-difluoro-2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-79-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-iodo-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-80-8 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(cyclopentyloxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-81-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(2-methylpropoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-82-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-83-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-84-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3,5-dichloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-85-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-86-4 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-(5-propoxy-2-pyridinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-87-5 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-nitro-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-88-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-89-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-90-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856166-91-1 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-(trifluoromethyl)-6-(2,2,2-trifluoro-1-methylethoxy)-3-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-92-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-amino-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-94-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856166-95-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl-

(CA INDEX NAME)



RN 856166-96-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856167-09-4 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-β-hydroxy-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856167-14-1 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856167-19-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, (αR,βR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 856167-21-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, (αR,βS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 856167-30-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-[(1-methylethyl)thio]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



IT 856166-58-0P, 3-[4-[5-[6-(3,3-Difluoropyrrolidin-1-yl)-5-

[(trimethylsilyl)ethynyl]pyridin-3-yl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists)

RN 856166-58-0 CAPLUS

CN Benzenepropanoic acid, 4-[5-[6-(3,3-difluoro-1-pyrrolidinyl)-5-[2-(trimethylsilyl)ethynyl]-3-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.12	404.10

FILE 'STNGUIDE' ENTERED AT 20:35:53 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 1, 2009 (20090501/UP).

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 20:38:11 ON 06 MAY 2009
FILE 'STNGUIDE' ENTERED AT 20:38:11 ON 06 MAY 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.07	404.17

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.07	404.17

FILE 'REGISTRY' ENTERED AT 20:38:20 ON 06 MAY 2009

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7
DICTIONARY FILE UPDATES: 5 MAY 2009 HIGHEST RN 1143038-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\123a.str





chain nodes :
21 22 23 24 25 27 29 43 44
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 26 28 30 31 32 33
34 35 36 37 38 39 40 41 42

```
ring/chain nodes :
18  20
chain bonds :
10-12  15-18  18-20  20-21  22-23  23-24  25-26  27-28  29-30  36-43  40-44
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-11  7-8  8-9  9-10  10-11  12-13  12-17  13-14
14-15  15-16  16-17  26-31  26-34  28-35  28-38  30-39  30-42  31-32  32-33  33-34
35-36  36-37  37-38  39-40  40-41  41-42
exact/norm bonds :
7-11  9-10  10-11  20-21  26-31  26-34  28-35  28-38  30-39  30-42  31-32  32-33
33-34  35-36  36-37  36-43  37-38  39-40  40-41  40-44  41-42
exact bonds :
7-8  8-9  10-12  15-18  18-20  25-26  27-28  29-30
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  12-13  12-17  13-14  14-15  15-16  16-17  22-23
23-24
isolated ring systems :
containing 1 : 7 : 12 :


G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:Atom  27:CLASS  28:Atom
29:CLASS  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  42:Atom  43:CLASS  44:CLASS  50:Atom




L8      STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\123.str
```





chain nodes :
21 22 23 24 25 27 29 43 44
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 26 28 30 31 32 33
34 35 36 37 38 39 40 41 42
ring/chain nodes :
18 20
chain bonds :
5-7 10-12 15-18 18-20 20-21 22-23 23-24 25-26 27-28 29-30 36-43 40-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17 26-31 26-34 28-35 28-38 30-39 30-42 31-32 32-33 33-34
35-36 36-37 37-38 39-40 40-41 41-42
exact/norm bonds :
7-11 8-9 9-10 10-11 20-21 26-31 26-34 28-35 28-38 30-39 30-42 31-32
32-33 33-34 35-36 36-37 36-43 37-38 39-40 40-41 40-44 41-42
exact bonds :
5-7 7-8 10-12 15-18 18-20 25-26 27-28 29-30
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 22-23
23-24
isolated ring systems :
containing 1 : 7 : 12 :

G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:Atom 27:CLASS 28:Atom
29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:CLASS 44:CLASS

```
L9      STRUCTURE UPLOADED

=> s l8 sss full
FULL SEARCH INITIATED 20:39:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L10           0 SEA SSS FUL L8

=> s l9 sss full
FULL SEARCH INITIATED 20:39:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       25 TO ITERATE

100.0% PROCESSED       25 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

L11           5 SEA SSS FUL L9

=> file capl
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 371.28     775.45

FILE 'CAPLUS' ENTERED AT 20:39:09 ON 06 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 May 2009  VOL 150 ISS 19
FILE LAST UPDATED: 5 May 2009  (20090505/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l11
L12           0 L11
```

=>